@article{0116ccdd56cf43159d5f9f0760b84ebd,
title = "The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities",
abstract = "The APOBEC3 family of cytosine deaminases are part of the innate immune response to viral infection, but also have the capacity to damage cellular DNA. Detection of mutational signatures consistent with APOBEC3 activity, together with elevated APOBEC3 expression in cancer cells, has raised the possibility that these enzymes contribute to oncogenesis. Genome deamination by APOBEC3 enzymes also elicits DNA damage response signaling and presents therapeutic vulnerabilities for cancer cells. Here, we discuss implications of APOBEC3 activity in cancer and the potential to exploit their mutagenic activity for targeted cancer therapies.",
keywords = "APOBEC3, Cytosine deaminase, DNA damage response, Mutational patterns, Synthetic lethality",
author = "Green, {Abby M.} and Weitzman, {Matthew D.}",
note = "Funding Information: We thank members of the Weitzman Lab for insightful discussions and input. We thank Rahul Kohli, Sebastien Landry, Daphne Avgousti, and Rachel DeWeerd for critical reading of the manuscript. A.M.G. was supported by a Young Investigator Award from the Alex{\textquoteright}s Lemonade Stand Foundation , and by the National Institutes of Health ( K12 CA076931 and K08 CA212299 ). Research on APOBEC enzymes in the Weitzman lab was supported by grants to M.D.W. from the National Institutes of Health ( CA181259 and CA185799 ). The authors declare that there are no conflicts of interest. Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",
year = "2019",
month = nov,
doi = "10.1016/j.dnarep.2019.102700",
language = "English",
volume = "83",
journal = "DNA Repair",
issn = "1568-7864",
}